Preview

Вестник трансплантологии и искусственных органов

Расширенный поиск

ПЕРСОНАЛИЗИРОВАННЫЙ ПОДХОД К ВЫБОРУ ИММУНОСУПРЕССИВНОЙ ТЕРАПИИ ПРИ ТРАНСПЛАНТАЦИИ СЕРДЦА

https://doi.org/10.15825/1995-1191-2018-1-127-137

Полный текст:

Аннотация

На сегодняшний день трансплантация сердца остается «золотым стандартом» лечения терминальной стадии хронической сердечной недостаточности. Применение иммуносупрессивной терапии в послеоперационном периоде направлено на предотвращение развития острого отторжения трансплантата и является краеугольным камнем в ведении этих пациентов. Однако развитие побочных эффектов от приема иммуносупрессивных препаратов является причиной снижения качества и ограничения продолжительности жизни. Задача персонализации иммуносупрессивной терапии, с одной стороны, заключается в сохранении функции трансплантата, а с другой – в минимизации побочных эффектов, возникающих на фоне иммуносупрессии. Цель нашего обзора – провести анализ протоколов назначения иммуносупрессивной терапии у различных групп реципиентов после трансплантации сердца.

Об авторах

Н. Н. Колоскова
ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России
Россия

Колоскова Надежда Николаевна

123182, Москва, ул. Щукинская, д. 1



В. Н. Попцов
ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России
Россия
Москва


А. О. Шевченко
ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия
Москва


Список литературы

1. Готье СВ. Иммуносупрессия при трансплантации солидных органов. М.–Тверь: Триада, 2011: 12–17.

2. Zabriskie JB. Essential clinical immunology. Cambridge University Press. 2009; 331–336.

3. Zuckermann A, Schulz U, Deuse T, Ruhpawar A et al. Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. Transpl. Int. 2015 Mar; 28 (3): 259–269.

4. Schweiger М. Immunosuppressive Therapy After Cardiac Transplantation. Medical University Graz, Department for Surgery, Division for Transplantation Surgery, Austria. 4–5.

5. Lars H Lund, Leah B Edwards, Anna Y Kucheryavaya et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Offi cial Adult Heart Transplantation Report–2015; Focus Theme: Early Graft Failure. The Journal of Heart and Lung Transplantation. 2015; 34 (10): 1245–1253.

6. Готье СВ. Иммуносупрессия при трансплантации солидных органов. М.–Тверь: Триада, 2011: 18–22.

7. Lindenfeld J, Miller GG, Shakar SF et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation. 2004; 110: 38–58.

8. Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA et al. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur. J. Clin. Pharmacol. 2010; 66: 1177–1187.

9. Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation. 2004; 78: 779–781.

10. Rosenberg PB, Vriesendorp AE, Drazner MH et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J. Heart. Lung. Transplant. 2005; 24: 1327–1331.

11. Aliabadi A, Grömmer M, Zuckermann A. Is induction therapy still needed in heart transplantation? Curr. Opin. Organ. Transplant. 2011; 16: 536–542.

12. Aliabadi A, Grömmer M, Cochrane A, Salameh O, Zuckermann A. Induction therapy in heart transplantation: where are we now? Transpl. Int. 2013; 26: 684–695.

13. Hosenpud JD, Bennett LE, Keck BM et al. The registry of the international society for heart and lung transplantation: fi fteenth offi cial report–1998. J. Heart. Lung. Transplant. 1998; 17: 656–668.

14. Yacoub M, Alivizatos P, Khaghani A, Mitchell A. The use of cyclosporine, azathioprine, and antithymocyte globulin with or without low-dose steroids for immunosuppression of cardiac transplant patients. Transplant. Proc. 1985; 17: 221–222.

15. Katz MR, Barnhart GR, Szentpetery S et al. Are steroids essential for successful maintenance of immunosuppression in heart transplantation? J. Heart. Lung. Transplant. 1987; 6: 293–297.

16. Oaks TE, Wannenberg T, Close SA et al. Steroid-Free Maintenance Immunosuppression After Heart Transplantation. Ann. Thorac. Surg. 2001; 72: 102–106.

17. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R et al. The Registry of the International Society for Heart and Lung Transplantation: twentyseventh offi cial adult heart transplant report – 2010. J. Heart. Lung. Transplant. Oct 2010; 29 (10): 1089–1103.

18. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am. J. Transplant. 2006; 6: 1377–1386.

19. Lehmkuhl HB, Arizon J, Vigano M et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation. 2009; 88: 115–122.

20. Kobashigawa JA, Pauly D, Kfoury A et al. Multicenter randomized trial of everolimus vs. mycophenolate mofetil in heart transplantation: fi nal 24 month analysis of effi cacy and safety. J. Heart. Lung. Transplant. 2012; 31: S73–S74.

21. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004; 110: 2694–2700.

22. Stehlik J, Edwards LB, Kucheryavaya AY et al. Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report – 2011. J. Heart. Lung. Transplant. 2011; 30: 1078–1079.

23. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr. Med. Chem. 2010; 17 (6): 571–584.

24. Wooten JM. Pharmacotherapy considerations in elderly adults. South. Med. J. 2012; 105 (8): 437–445.

25. Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J. Gen. Intern. Med. 2011; 26 (7): 783–790.

26. Gill J, Sampaio M, Gill JS et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin. J. Am. Soc. Nephrol. 2011; 6 (5): 1168–1178.

27. Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann. Surg. 2008; 248 (4): 564–577.

28. Badowski M, Gurk-Turner C, Cangro C et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin. Transplant. 2009; 23 (6): 930–937.

29. Baran D, Zucker M, Arroyo L et al. A prospective, randomized trial of singledrug versus dual-drug immunosuppression in heart transplantation: the Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) trial. Circ. Heart. Fail. 2011; 4: 129–137.

30. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with targetofrapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005; 80 (7): 883–889.

31. Delgado DH, Miriuka SG, Cusimano RJ et al. Use of basiliximab and cyclosporine in heart transplant patients with preoperative renal dysfunction. J. Heart. Lung. Transplant. 2005; 24: 166–169.

32. Rosenberg PB, Vriesendorp AE, Drazner MH et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J. Heart. Lung. Transplant. 2005; 24: 1327–1331.

33. Meiser B, Reichart B, Adamidis I et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am. J. Transplant. 2005; 5: 827–831.

34. Stypmann J, Engelen MA, Eckernkemper S, Amler S, Gunia S et al. Calcineurin Inhibitor-free Immunosuppression Using Everolimus (Certican) after Heart Transplantation: 2 years’ Follow-up from the University Hospital Münster. Transplantation Proceedings. 2011; 43: 1847–1852.

35. Lucan VC, Berardinelli L. Gastrointestinal Side Effects of Post-Transplant Therapy. J. Gastrointestin. Liver. Dis. September 2016; 25 (3): 367–373.

36. Angarone M, Ison MG. Diarrhea in solid organ transplant recipients. Curr. Opin. Infect. Dis. 2015 Aug; 28 (4): 308–316.

37. Maesa B, Hadayab K, de Moor B. Severe Diarrhea in Renal Transplant Patients: Results of the DIDACT Study. American Journal of Transplantation. 2006; 6: 1466–1472.

38. Yang J, Hutchinson II, Shah T, Min DI. Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation. 2011; 91: 1114–1119.

39. Garro R, Warshaw B, Felner E. New-onset diabetes after kidney transplant in children. Pediatr Nephrol. 2015; 30: 405–416.

40. Prokai A, Fekete A, Kis E, Reusz GS, Sallay P, Korner A et al. Post-transplant diabetes mellitus in children following renal transplantation. Pediatr Transplant. 2008; 12: 643–649.

41. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J. Am. Soc. Nephrol. 2002; 13: 1374–1380.

42. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation. 1998; 65: 515–523.

43. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J. Transplant. 2007; 7: 1506–1514.

44. Porrini E, Moreno JM, Osuna A et al. Prediabetes in patients receiving tacrolimus in the fi rst year after kidney transplantation: a prospective and multicenter study. Transplantation. 2008; 85: 1133–1138.

45. Vincenti F, Schena FP, Paraskevas S, Hauser IA et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am. J. Transplant. 2008; 8 (2): 307–316.

46. Shivaswamy V, Boerner B, Larsen J. Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. Endocrine Reviews. 2016; 37 (1): 37–36.

47. Kobashigawa JA, Mehra M, West L et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J. Heart. Lung. Transplant. 2009; 28: 213–225.

48. Arnaoutakis GJ, George TJ, Kilic A, Weiss ES, Russell SD, Conte JV et al. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. J. Thorac. Cardiovasc. Surg. 2011; 142 (5): 1236–1245.

49. Oaks M, Michel K, Sulemanjee NZ, Thohan V, Downey FX. Practical value of identifying antibodies to cryptic HLA epitopes in cardiac transplantation. J. Heart. Lung. Transplant. 2014; 33 (7): 713–720.

50. Rummler S, Barz D. Plasma Exchange and Immunoadsorption of Patients with Thoracic Organ Transplantation. Transfusion Med Hemother: Offi zielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2012; 39 (4): 234–240.

51. Kobashigawa JA, Miller LW, Russell SD, Ewald GA et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am. J. Transplant: Off J. Am. Soc. Transplant. Am. Soc. Transplant. Surg. 2006; 6 (6): 1377–1386.

52. Liefeldt L, Brakemeier S, Glander P, Waiser J, Lachmann N, Schonemann C et al. Donor-specifi c HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am. J. Transplant: Off J. Am. Soc. Transplant. Am. Soc. Transplant. Surg. 2012; 12 (5): 1192–1198.

53. Kamar N, Del Bello A, Congy-Jolivet N, Guilbeau-Frugier C, Cardeau-Desangles I, Fort M et al. Incidence of donor-specifi c antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitorfree regimen. Clin. Transpl. 2013; 27 (3): 455–462.

54. Sikma1 MA, van Maarseveen EM, van de Graaf EA, Kirkels JH et al. Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. American Journal of Transplantation. 2015; 15: 2301–2313.

55. Shekar K, Fraser JF, Smith MT et al. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J. Crit. Care. 2012; 27: 741.

56. Shekar K, Roberts JA, McDonald CI et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit. Care. 2012; 16: R194.

57. Amy L Dzierba, Darryl Abrams, Daniel Brodie. Medicating patients during extracorporeal membrane oxygenation: the evidence is building. Crit. Care. 2017; 21 (1): 66–69.

58. David Shitrita, Alex Yussimb, Mordechai R Kramer. Role of siroliumus, a novel immunosuppressive drug in heart and lung transplantation Respiratory Medicine. 2004; 98: 892–897.

59. Dirk RJ Kuypers, Yannick Le Meur, Marcelo Cantarovich et al. The Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clin. J. Am. Soc. Nephrol. 2010; 5: 341–358.

60. Niloufar Mohammadpour, Sepideh Elyasi, Naser Vahdati. A Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs. Iranian Journal of Basic Medical Sciences. 2011; 14 (6): 485–498.


Для цитирования:


Колоскова Н.Н., Попцов В.Н., Шевченко А.О. ПЕРСОНАЛИЗИРОВАННЫЙ ПОДХОД К ВЫБОРУ ИММУНОСУПРЕССИВНОЙ ТЕРАПИИ ПРИ ТРАНСПЛАНТАЦИИ СЕРДЦА. Вестник трансплантологии и искусственных органов. 2018;20(1):127-137. https://doi.org/10.15825/1995-1191-2018-1-127-137

For citation:


Koloskova N.N., Poptsov V.N., Shevchenko A.О. THE INDIVIDUAL TAILORING OF IMMUNOSUPPRESSIVE THERAPY AFTER HEART TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2018;20(1):127-137. (In Russ.) https://doi.org/10.15825/1995-1191-2018-1-127-137

Просмотров: 213


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)